Q3 Earnings Beat for Cigna, Estee Lauder; Biogen Lowers FY Outlook; Citi Raises Alphabet Target

By / / Breaking News

Key Takeaways

  • Cigna (CI) significantly surpassed Q3 2025 expectations with adjusted revenue of $69.57 billion and adjusted operating EPS of $7.83, while reaffirming its full-year adjusted operating EPS outlook.
  • Estee Lauder (EL) reported robust Q1 2025 results, with net sales reaching $3.5 billion and adjusted EPS of $0.32, substantially beating analyst estimates.
  • Biogen (BIIB) exceeded Q3 2025 product revenue estimates at $1.85 billion and reported $4.81 adjusted EPS, but revised its full-year adjusted EPS guidance downward to $14.50-$15.00.
  • Citigroup (C) has increased its price target for Alphabet Inc. (GOOGL, GOOG) shares to $343 from $280, reflecting a positive analyst sentiment.

Cigna Delivers Strong Q3 Performance Amidst Dynamic Environment

Global health company Cigna (CI) announced a strong third quarter for 2025, reporting adjusted revenues of $69.57 billion, outperforming analyst estimates of $67.39 billion. The company's adjusted operating earnings per share (EPS) reached $7.83, comfortably exceeding the consensus estimate of $7.64.

A key driver for this performance was the Evernorth Health Services segment, which saw adjusted revenues climb to $60.39 billion, surpassing estimates of $58.78 billion. Cigna's medical care ratio improved to 84.8%, better than the anticipated 85.2%. The company also reaffirmed its full-year 2025 adjusted operating EPS outlook of at least $29.60, aligning closely with analyst expectations.

Estee Lauder's Q1 Exceeds Expectations

Estee Lauder Companies Inc. (EL) reported impressive fiscal first-quarter 2025 results, with net sales reaching $3.5 billion, significantly higher than the estimated $3.382 billion. The beauty giant's adjusted EPS came in at $0.32, well above the analyst consensus of $0.18 to $0.19.

The company's performance was bolstered by strong segment results, with Skin Care revenue hitting $1.58 billion against an estimated $1.56 billion. Makeup revenue met expectations at $1.03 billion. Despite a net income of $47 million for the quarter, Estee Lauder reaffirmed its fiscal year 2026 outlook, including organic net sales growth of 0% to +3%.

Biogen Lowers Full-Year EPS Guidance Despite Q3 Beat

Biogen (BIIB) posted third-quarter 2025 revenues of $2.5 billion and adjusted EPS of $4.81, both exceeding analyst expectations. Product revenue specifically reached $1.85 billion, surpassing the estimated $1.78 billion.

However, the pharmaceutical company revised its full-year 2025 adjusted EPS guidance downwards to a range of $14.50-$15.00, from a previous outlook of $15.50-$16.00. This updated outlook includes an anticipated $1.25 EPS impact stemming from development transactions.

Citigroup Boosts Alphabet Target Price

Citigroup (C) has shown increased confidence in Alphabet Inc. (GOOGL, GOOG), raising its price target for the tech giant's shares to $343 from the previous $280. This upward revision by the financial institution indicates a positive outlook on Alphabet's future performance and market valuation.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top